These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 39376788)

  • 1. Efficacy and Safety of Nicotinamide 10%, Associated with Magnesium Ascorbyl Phosphate 5% and Hyaluronic Acid 5%, Compared to Hydroquinone 4% in Women with Facial Melasma: A Randomized, Double-Blind, Controlled Clinical Trial.
    Barbosa M; de Amorim RP; Cassiano D; Dias M; de Abreu AF; Bagatin E; Miot HA; Espósito ACC
    Clin Cosmet Investig Dermatol; 2024; 17():2215-2223. PubMed ID: 39376788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential therapy with topical clobetasol for 14 days followed by hydroquinone versus hydroquinone alone in facial melasma treatment: a randomized, double-blind, controlled clinical trial.
    de Amorim RP; Barbosa MMC; Cassiano DP; Esposito ACC; Dias MO; de Abreu AFT; Bagatin E; Miot HA
    Int J Dermatol; 2024 Sep; 63(9):1221-1226. PubMed ID: 38411257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of topical isobutylamido thiazolyl resorcinol (Thiamidol) vs. 4% hydroquinone cream for facial melasma: an evaluator-blinded, randomized controlled trial.
    Lima PB; Dias JAF; Cassiano DP; Esposito ACC; Miot LDB; Bagatin E; Miot HA
    J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):1881-1887. PubMed ID: 33988887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study of topical 5% cysteamine versus 4% hydroquinone in the treatment of facial melasma in women.
    Lima PB; Dias JAF; Cassiano D; Esposito ACC; Bagatin E; Miot LDB; Miot HA
    Int J Dermatol; 2020 Dec; 59(12):1531-1536. PubMed ID: 32864760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. French maritime pine bark extract (pycnogenol) in association with triple combination cream for the treatment of facial melasma in women: a double-blind, randomized, placebo-controlled trial.
    Lima PB; Dias JAF; Esposito ACC; Miot LDB; Miot HA
    J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):502-508. PubMed ID: 32841433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, controlled, split-face, double-blind comparison of a multimodality pigment-correcting serum containing lotus sprout extract versus hydroquinone for moderate to severe facial hyperpigmentation, including melasma, in a diverse population.
    Huang P; Acevedo SF; Cheng T; Mehta RC; Makino ET
    JAAD Int; 2024 Jun; 15():206-219. PubMed ID: 38707930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of a 755-nm picosecond laser and hydroquinone 2% cream versus hydroquinone 2% cream alone for the treatment of melasma: A randomized, split-face, and controlled trial.
    Manuskiatti W; Yan C; Gulfan MCB; Techapichetvanich T; Wanitphakdeedecha R
    Lasers Surg Med; 2022 Dec; 54(10):1245-1250. PubMed ID: 36345697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, Double-Blinded, Split-Face Study Comparing the Efficacy and Tolerability of Two Topical Products for Melasma.
    Kaufman BP; Alexis AF
    J Drugs Dermatol; 2020 Sep; 19(9):822-827. PubMed ID: 33026755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability on melasma of a topical cosmetic product acting on melanocytes, fibroblasts and endothelial cells: a randomized comparative trial against 4% hydroquinone.
    Bronzina E; Clement A; Marie B; Fook Chong KT; Faure P; Passeron T
    J Eur Acad Dermatol Venereol; 2020 Apr; 34(4):897-903. PubMed ID: 31858658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the therapeutic efficacy and safety of combined oral tranexamic acid and topical hydroquinone 4% treatment vs. topical hydroquinone 4% alone in melasma: a parallel-group, assessor- and analyst-blinded, randomized controlled trial with a short-term follow-up.
    Lajevardi V; Ghayoumi A; Abedini R; Hosseini H; Goodarzi A; Akbari Z; Hedayat K
    J Cosmet Dermatol; 2017 Jun; 16(2):235-242. PubMed ID: 27762489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fractional erbium:YAG laser (2940 nm) plus topical hydroquinone compared to intradermal tranexamic acid plus topical hydroquinone for the treatment of refractory melasma: a randomized controlled trial.
    Mokhtari F; Bahrami B; Faghihi G; Asilian A; Iraji F
    J Dermatolog Treat; 2022 Aug; 33(5):2475-2481. PubMed ID: 34387527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of a novel picosecond laser using combination of 1 064 and 595 nm on patients with melasma: A prospective, randomized, multicenter, split-face, 2% hydroquinone cream-controlled clinical trial.
    Choi YJ; Nam JH; Kim JY; Min JH; Park KY; Ko EJ; Kim BJ; Kim WS
    Lasers Surg Med; 2017 Dec; 49(10):899-907. PubMed ID: 28906574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the efficacy of cysteamine cream compared to hydroquinone in the treatment of melasma: A randomised, double-blinded trial.
    Nguyen J; Remyn L; Chung IY; Honigman A; Gourani-Tehrani S; Wutami I; Wong C; Paul E; Rodrigues M
    Australas J Dermatol; 2021 Feb; 62(1):e41-e46. PubMed ID: 32981068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the efficacy and safety of combinations of hydroquinone, glycolic acid, and hyaluronic acid in the treatment of melasma.
    Ibrahim ZA; Gheida SF; El Maghraby GM; Farag ZE
    J Cosmet Dermatol; 2015 Jun; 14(2):113-23. PubMed ID: 25847063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of Plasma Rich in Growth Factors With Topical 4% Hydroquinone Compared With Topical 4% Hydroquinone Alone in the Treatment of Dermal Type of Melasma: A Single-Blinded Randomized Split-Face Study.
    Amiri R; Karimi Maskooni M; Farsinejad A; Karvar M; Khalili M; Aflatoonian M
    Indian Dermatol Online J; 2024; 15(4):593-598. PubMed ID: 39050052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind, Placebo-controlled Trial to Evaluate the Effectiveness of
    Goh CL; Chuah SY; Tien S; Thng G; Vitale MA; Delgado-Rubin A
    J Clin Aesthet Dermatol; 2018 Mar; 11(3):14-19. PubMed ID: 29606995
    [No Abstract]   [Full Text] [Related]  

  • 17. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma.
    Chan R; Park KC; Lee MH; Lee ES; Chang SE; Leow YH; Tay YK; Legarda-Montinola F; Tsai RY; Tsai TH; Shek S; Kerrouche N; Thomas G; Verallo-Rowell V
    Br J Dermatol; 2008 Sep; 159(3):697-703. PubMed ID: 18616780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the efficacy and safety of picosecond Nd:YAG laser (1,064 nm), picosecond alexandrite laser (755 nm) and 2% hydroquinone cream in the treatment of melasma: A randomized, controlled, assessor-blinded trial.
    Liang S; Shang S; Zhang W; Tan A; Zhou B; Mei X; Li L
    Front Med (Lausanne); 2023; 10():1132823. PubMed ID: 37056729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled clinical trial on the efficacy and safety of 3% Rumex occidentalis cream versus 4% hydroquinone cream in the treatment of melasma among Filipinos.
    Mendoza CG; Singzon IA; Handog EB
    Int J Dermatol; 2014 Nov; 53(11):1412-6. PubMed ID: 25265986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia.
    Wang J; Fabi S; Robinson D; Bajaj S; Geronemus R; Bell M; Widgerow A
    J Drugs Dermatol; 2023 Apr; 22(4):333-338. PubMed ID: 37026875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.